Johnson & Johnson released new studies this month examining the efficacy of robotic-assisted bronchoscopy (RAB) delivered through its Monarch platform. The research, presented at the American College ...

Please provide your email address to receive an email when new articles are posted on . The FDA cleared the use of NeuroSigma’s second-generation Monarch eTNS System for treating pediatric ADHD. The ...

Trial to be conducted at UCLA and funded by a grant from National Institute on Alcohol Abuse and Alcoholism (NIAAA) First phase of trial will enroll up to 30 children ages 8 – 12 with exposure to ...

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation ...

Monarch 2.0 significantly improves upon the first-generation Monarch eTNS System. The device is approximately one-third the size, includes a high-resolution color LCD screen and optimized user ...